Drug Pipeline

TLL-018 Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
3
Active Studies
1
Recruiting
3
Phase 3
1
Top Sponsors
2
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-05-23 NCT06020144
A Phase 3 Study Comparing TLL-018 to Tofacitinib in RA Subjects With Inadequate Response…		 date change Primary completion moved earlier: 2026-07-31 -> 2026-01-15
2026-05-23 NCT06020144
A Phase 3 Study Comparing TLL-018 to Tofacitinib in RA Subjects With Inadequate Response…		 date change Completion moved earlier: 2028-12-30 -> 2026-12-31
Active Studies by Phase
Phase 3
3
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT06887127 A Long-term Extension Clinical Study of TLL-018 in Patients With Rheumatoid Arthritis Rheumatoid Arthritis Recruiting
NCT06020144 A Phase 3 Study Comparing TLL-018 to Tofacitinib in RA Subjects With Inadequate Response… Rheumatoid Arthritis Active, Not Recruiting
NCT06396026 A Study of Efficacy and Safety of TLL-018 in CSU Participants Chronic Spontaneous Urticaria Active, Not Recruiting
Sponsors Running TLL-018 Trials
Hangzhou Highlightll Pharmaceutical Co., Ltd (3)
Disease Areas
Rheumatoid Arthritis (2)
Get alerts when TLL-018 trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free